Common use of Cautionary Note Regarding Forward Clause in Contracts

Cautionary Note Regarding Forward. Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration and license agreement among Blueprint Medicines and Roche, including anticipated payments, as well as the future development, manufacture and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines’ and Roche’s ability to successfully develop and commercialize cancer immunotherapies; and Blueprint Medicines' strategy and business plans. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines' Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (SEC) on March 11, 2016, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. Contact: Investor Relations: Xxxxxxx Xxxxxxxx Blueprint Medicines Corporation 000-000-0000 XXxxxxxxx@xxxxxxxxxxxxxxxxxx.xxx Media Relations: Xxx Xxxxx Ten Bridge Communications, Inc. 000-000-0000 xxx@xxxxxxxxxxxxxxxxxxxxxxx.xxx AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Amendment, effective April 15, 2016 (“Effective Date”), is by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000 Xxxxx, Xxxxxxxxxxx and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 (“Blueprint”).

Cautionary Note Regarding Forward. Looking Statements This press release contains and statements of our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve significant risks and uncertainties that may cause the actual results (including, without limitation (i) whether we will exercise the option with the University of Pittsburgh, or the benefits of the technology subject to such option and (ii) whether we will be able to close our proposed merger with Bull Horn Holdings Corp., each as described herein) to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. All forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, are subject to significant uncertainties and risks including, without limitationbut not limited, statements regarding to those risks contained or to be contained in reports and other filings filed by us with the collaboration Securities and license agreement Exchange Commission. For these reasons, among Blueprint Medicines and Rocheothers, including anticipated payments, as well as the future development, manufacture and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines’ and Roche’s ability investors are cautioned not to successfully develop and commercialize cancer immunotherapies; and Blueprint Medicines' strategy and business plans. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any place undue reliance upon any forward-looking statements in this press release release. Additional factors are based on management's current expectations and beliefs and are subject discussed in our filings made or to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines' Annual Report on Form 10-K for the year ended December 31, 2015, as filed be made with the U.S. Securities and Exchange Commission (SEC) on March 11Commission, 2016, and other filings that Blueprint Medicines may make with the SEC in the futurewhich are available for review at xxx.xxx.xxx. Any We undertake no obligation to publicly revise these forward-–looking statements contained in this press release represent Blueprint Medicines' views only as of to reflect events or circumstances that arise after the date hereof and should not be relied upon as representing its views as of any subsequent dateunless required by applicable laws, regulations or rules. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. Contact: Investor Relations: Xxxxxxx Xxxxxxxx Blueprint Medicines Corporation 000-000-0000 XXxxxxxxx@xxxxxxxxxxxxxxxxxx.xxx Media Relations: Xxx Xxxxx Ten Bridge Communications, Inc. 000-000-0000 xxx@xxxxxxxxxxxxxxxxxxxxxxx.xxx AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Amendment, effective April 15, 2016 (“Effective Date”), is by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000 Xxxxx, Xxxxxxxxxxx and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 (“Blueprint”).CONTACTS

Cautionary Note Regarding Forward. Looking Statements This press release contains forward-looking statements within the meaning of the The Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, . Such forward-looking statements include those regarding the potential benefits of, and plans relating to, the collaboration with Celgene; the potential benefits of AG-221, AG-120 and license agreement among Blueprint Medicines and Roche, including anticipated payments, as well as the future development, manufacture and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines’ and Roche’s ability to successfully develop and commercialize cancer immunotherapiesAG-881; and Blueprint Medicines' strategy Agios’ plans to generate data from AG-881 to inform its future development plans; and business plansthe benefit of Agios’ strategic plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “potentialcould,” “continue,” “targetwould” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking Such statements in this press release are based on management's current expectations and beliefs and are subject to a number of risksnumerous important factors, risks and uncertainties and important factors that may cause actual events or results to differ materially from those expressed Agios’ current expectations and beliefs. For example, there can be no guarantee that AG-881 or implied by any other product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements contained in this press release, including, without limitation, release could also be affected by risks and uncertainties related relating to a number of other important factors, including: Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the delay content and timing of any current or decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 trials; unplanned cash requirements and BLU-554expenditures; Blueprint Medicines' advancement of multiple early-stage effortscompetitive factors; Blueprint Medicines' Agios’ ability to successfully demonstrate the efficacy obtain, maintain and safety of its drug enforce patent and other intellectual property protection for any product candidatescandidates it is developing; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidatesAgios’ ability to maintain key collaborations; and actions of regulatory agencies, which may affect the initiation, timing general economic and progress of clinical trialsmarket conditions. These and other risks and uncertainties are described in greater detail in under the section entitled caption “Risk Factors” included in Blueprint Medicines' Agios’ Annual Report on Form 10-K for the year ended December 31, 20152014, as filed and other filings that Agios may make with the Securities and Exchange Commission (SEC) on March 11, 2016, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views speak only as of the date hereof hereof, and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. ### Contact: Investor Relations: Xxxxxxx Xxxxxxxx Blueprint Medicines Corporation Agios Pharmaceuticals, Inc. Xxxx Xxxx, 000-000-0000 XXxxxxxxx@xxxxxxxxxxxxxxxxxx.xxx Media Relations: Xxx Xxxxx Ten Bridge CommunicationsSenior Director, Inc. 000-000-0000 xxx@xxxxxxxxxxxxxxxxxxxxxxx.xxx AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This AmendmentInvestor Relations and Public Relations xxxx.xxxx@xxxxx.xxx Exhibit H Initial JSC, effective April 15, 2016 JDC and JPC Appointments Joint Steering Committee (“Effective Date”JSC) Position Celgene Appointee Agios Appointee Initial Chairperson [**] [**] JSC Member [**] [**] JSC Member [**] [**] JSC Member [**] [**] Joint Development Committee (JDC) Position Celgene Appointee Agios Appointee Initial Chairperson [**] [**] JDC Member [**] [**] JDC Member [**] [**] JDC Member [**] [**] Joint Patent Committee (JPC) Position Celgene Appointee Agios Appointee Initial Chairperson [**] [**] JPC Member [**] [**] JPC Member [**] [**] Exhibit I Partnership Tax Matters (See attached.), is by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000 Xxxxx, Xxxxxxxxxxx and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 (“Blueprint”).

Cautionary Note Regarding Forward. Looking Statements This press release contains forward-looking statements within the meaning as that term is defined in Section 27A of the Private Securities Litigation Reform Act of 19951933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, as amended, including, without limitationamong other things, statements regarding ORIC-114’s effectiveness in brain penetrance and selectivity against exon 20 insertion mutations of EGFR and HER2, the collaboration potential benefits of and activity under the license agreement among Blueprint Medicines between ORIC and RocheVoronoi; development plans underlying ORIC-114, including anticipated paymentsinitiation of a global Phase 1/2 tumor-agnostic trial of ORIC-114 in genetically defined cancers in the second half of 2021; the potential best-in-class nature of the EGFR and HER2 exon 20 inhibitor program, as well as including ORIC-114; the future development, manufacture potential advantages of ORIC’s product candidates; statements by ORIC’s president and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines’ and Roche’s ability to successfully develop and commercialize cancer immunotherapieschief executive officer; and Blueprint Medicines' strategy and business statements by Voronoi’s chief executive officer. Words such as “believes,” “anticipates,” “plans. The words ,” “mayexpects,” “intends,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “projectgoal,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all . The forward-looking statements contain these identifying words. Any forward-looking statements in this press release contained herein are based on management's upon ORIC’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors involve assumptions that may cause actual events never materialize or may prove to be incorrect. Actual results to could differ materially from those expressed or implied by projected in any forward-looking statements contained in this press release, including, without limitation, due to numerous risks and uncertainties related uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to the delay of any current develop, initiate or planned complete preclinical studies and clinical trials or the development for, obtain approvals for and commercialize any of Blueprint Medicines' drug its product candidates, including BLU-285 ; changes in ORIC’s plans to develop and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of commercialize its drug product candidates; the preclinical potential for clinical trials of ORIC-101, ORIC-944, ORIC-533, ORIC-114 or any other product candidates to differ from preclinical, preliminary or expected results; negative impacts of the COVID-19 pandemic on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of the license agreement; risks related to the effect of the announcement of the transaction on ORIC’s business relationships, operating results and clinical results business generally; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including Voronoi, contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for Blueprint Medicines' drug product candidates, which may not support further development of such drug its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These market conditions; and other risks. Information regarding the foregoing and additional risks and uncertainties are described in greater detail may be found in the section entitled “Risk Factors” in Blueprint Medicines' Annual ORIC’s Quarterly Report on Form 10-K for the year ended December 31, 2015, as Q filed with the Securities and Exchange Commission (the “SEC”) on March 11August 5, 20162020, and other filings that Blueprint Medicines may make ORIC’s future reports to be filed with the SEC in the futureSEC. Any These forward-looking statements contained in this press release represent Blueprint Medicines' views only are made as of the date hereof of this press release, and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any ORIC assumes no obligation to update any the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact: Investor Relations: Xxxxxxx Xxxxxxxx Blueprint Medicines Corporation 000-000-0000 XXxxxxxxx@xxxxxxxxxxxxxxxxxx.xxx Media Relations: Xxx Xxxxx Ten Bridge CommunicationsDxxxxxx Xxxxxxxxxx, Inc. 000-000-0000 xxx@xxxxxxxxxxxxxxxxxxxxxxx.xxx AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Amendment, effective April 15, 2016 (“Effective Date”), is by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000 Xxxxx, Xxxxxxxxxxx and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 (“Blueprint”).Chief Financial Officer dxxxxxx.xxxxxxxxxx@xxxxxxxxxx.xxx ixxx@xxxxxxxxxx.xxx Schedule 13.1 Disclosure Schedule [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]

Cautionary Note Regarding Forward. Looking Statements ​ This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration and license agreement among Blueprint Medicines and Roche, including anticipated payments, as well as the future development, manufacture and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines’ and Roche’s ability to successfully develop and commercialize cancer immunotherapies; and Blueprint Medicines' strategy and business plans. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” ​ “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines' Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (SEC) on March 11, 2016, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. ​ Contact: ​ Investor Relations: Xxxxxxx Xxxxxxxx Blueprint Medicines Corporation 000-000-0000 XXxxxxxxx@xxxxxxxxxxxxxxxxxx.xxx ​ ​ ​ Media Relations: Xxx Xxxxx Ten Bridge Communications, Inc. 000-000-0000 xxx@xxxxxxxxxxxxxxxxxxxxxxx.xxx AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Amendment, effective April 15, 2016 (“Effective Date”), is by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000 Xxxxx, Xxxxxxxxxxx and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 (“Blueprint”).​

Cautionary Note Regarding Forward. Looking Statements LOOKING INFORMATION This press release contains prospectus, any accompanying prospectus supplement, and the documents incorporated by reference herein and therein, include forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act of 19951933, as amended, includingor the Securities Act, without limitationand Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this prospectus, any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, including statements regarding the collaboration estimates, future events, our future financial performance, business strategy and license agreement among Blueprint Medicines plans and Rocheobjectives of management for future operations, including anticipated paymentswith respect to us specifically and the cancer diagnostics industry in general, as well as the future development, manufacture are forward-looking statements. We have attempted to identify estimates and commercialization of cancer immunotherapies under the agreement; Blueprint Medicines’ and Roche’s ability to successfully develop and commercialize cancer immunotherapies; and Blueprint Medicines' strategy and business plans. The words forward-looking statements by terminology including “mayaims,” “willanticipates,” “believes,” “can,” “continue,” “could,” “wouldestimates,” “expects,” “goal,” “intends,” “may,” “plans,” “potential,” “predicts,” “seeks,” “should,” “expectsuggests,” “plan,targets” or “anticipate,will” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although or the negative of these terms or other comparable terminology. Although we do not all make estimates or forward-looking statements contain these identifying wordsunless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Any Our estimates and forward-looking statements in this press release are based on management's our current assumptions and expectations about future events and beliefs trends, which affect or may affect our business, strategy, operations or financial performance. These statements are only predictions and are subject to a number of involve known and unknown risks, uncertainties and important factors that other factors, which may cause our or our industry’s actual events results, levels of activity, performance or results achievements to differ vary materially from those expressed or implied by any these estimates and forward-looking statements contained statements. Factors that could cause or contribute to such differences in this press releaseresults and outcomes include, includingbut are not limited to, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These and other risks and uncertainties are described in greater detail in those discussed under the section entitled “Risk Factors” in Blueprint Medicines' Annual Report on Form 10-K for the year ended December 31this prospectus, 2015, as filed with the Securities and Exchange Commission (SEC) on March 11, 2016any accompanying prospectus supplement, and in any documents incorporated by reference herein and therein. Readers should carefully review this information as well as other risks and uncertainties described in other filings that Blueprint Medicines may make with the SEC that we may make after the filing date of this prospectus. See the information included under the heading “Where You Can Find More Information.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the futureimpact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any estimates or forward- looking statements. Any All estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by applicable law or regulation, we undertake no obligation to update or to review any estimate and/or forward-looking statement. In light of these risks and uncertainties, we cannot assure you that the estimates or forward-looking statements contained in this press release represent Blueprint Medicines' views only as of prospectus, any accompanying prospectus supplement, or the date hereof and documents incorporated by reference herein or therein, will in fact occur. You should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any place undue reliance on these estimates and forward-looking statements. Contact: Investor Relations: Xxxxxxx Xxxxxxxx Blueprint Medicines Corporation 000We qualify all of our forward-000-0000 XXxxxxxxx@xxxxxxxxxxxxxxxxxx.xxx Media Relations: Xxx Xxxxx Ten Bridge Communications, Inc. 000-000-0000 xxx@xxxxxxxxxxxxxxxxxxxxxxx.xxx AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Amendment, effective April 15, 2016 (“Effective Date”), is looking statements by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000 Xxxxx, Xxxxxxxxxxx and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 (“Blueprint”)these cautionary statements.